"Best Buy" NSAID Rxs Up Since Vioxx Withdrawal, But Mobic Growing Faster, Consumers Union Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Prescriptions for Abbott/Boehringer Ingelheim's Mobic doubled from September to March and the average retail price rose 9% in the same period, Consumers Union notes. Scripts for ibuprofen were up 28%, but prices were "relatively flat," the report says.
You may also be interested in...
Mobic Generic Competition Possible In Early 2006
Boehringer Ingelheim brand rings up $293 mil. in first quarter sales as biggest beneficiary from COX-2 safety issues. Mobic loses exclusivity April 13, although generics are unlikely to enter the market for at least nine months.
Abbott/Boehringer's Mobic Sales Surge On COX-2 Safety Concerns
Sales of the non-steroidal anti-inflammatory agent jumped 177% in the fourth quarter on the heels of Merck's withdrawal of Vioxx. Abbott expects sales of Mobic to reach $1 bil. in 2005. The levothyroxine brand Synthroid is retaining 70% of the share it held before entry of generic competition.
Lipitor, Lovastatin Are “Best Buy” Statins, Consumers Union Says
Pfizer’s statin is rated the best value for patients needing to reduce LDL cholesterol more than 40%, but generic lovastatin is best for patients needing a smaller reduction. Consumer Reports publisher posts drug comparison reports for statins, NSAIDs and PPIs on its website.